Night sweats
Current understanding
Constitutional symptom driven by inflammatory cytokine signaling.
Evidence log
- 2026-06-12 — Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study.: 2026 — MFSAF v4.0 mixed-methods validation in MF confirmed the night-sweats item as content-valid and reliable, with a 1–2-point within-item change judged meaningful by patients — supporting its use to quantify cytokine-driven night sweats in MF trial endpoints. (novelty: 3)
- 2026-03-27 — Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms: 2026 — Phase II curcumin trial in CCUS/LR-MDS/MPN includes constitutional symptom burden among endpoints, testing whether anti-inflammatory supplementation reduces cytokine-driven symptoms such as night sweats. (novelty: 3)
Open questions
Related
Contributing findings
How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?
23-oct-2026
novelty 2
per-area 1
mentions
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
13-aug-2026
novelty 2
per-area 1
mentions
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
11-aug-2026
novelty 2
per-area 1
mentions
SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis.
24-jul-2026
novelty 2
per-area 1
mentions
SOHO State of the Art Updates and Next Questions| Individualizing Treatment Selection in Myelofibrosis.
23-jul-2026
novelty 2
per-area 1
mentions
Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation.
13-jul-2026
novelty 2
per-area 1
mentions
Implementation of a nurse-led visit and follow-up for patients with myeloproliferative neoplasms: a quality improvement project.
03-jul-2026
novelty 2
per-area 2
mentions
Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study.
12-jun-2026
novelty 3
per-area 2
mentions
What MPN Symptom Caught You Most Off Guard—and How Do You Manage It Now?
22-apr-2026
novelty 1
per-area 1
mentions
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
14-apr-2026
novelty 3
per-area 2
mentions
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
27-mar-2026
novelty 3
per-area 2
mentions
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
06-feb-2026
novelty 4
per-area 2
mentions